

# Unique



## J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:

"NEELAM CENTRE", 'B' WING, 4TH FLR.,  
HIND CYCLE ROAD, WORLI,  
MUMBAI - 400 030.

PHONE : 022-2482 2222 / 2493 0918

FAX : 022-2493 0534 / 2493 9633

e-mail : info@jbcpl.com

Website : www.jbcpl.com

CIN : L24390MH1976PLC019380

### STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30/09/2015

(Rs. in lakhs)

Sl.No.	PART I - Particulars	Quarter ended			Half Year		Year ended
		30/09/2015	30/06/2015	30/09/2014	30/09/2015	30/09/2014	31/03/2015
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	<b>Income from Operations</b>						
	a. Net sales (Net of excise duty)	28,070.95	27,914.93	27,486.10	55,985.88	53,157.31	1,03,813.61
	b. Other Operating Income	607.15	505.92	539.67	1,113.07	1,128.74	2,328.51
	<b>Total Income from Operations (Net) (a+b)</b>	<b>28,678.10</b>	<b>28,420.85</b>	<b>28,025.77</b>	<b>57,098.95</b>	<b>54,286.05</b>	<b>1,06,142.12</b>
2	<b>Expenses</b>						
	a. Cost of materials consumed	9,819.75	9,022.98	8,703.83	18,842.73	17,042.47	34,158.73
	b. Purchases of stock-in-trade	2,003.69	2,309.10	3,070.88	4,312.79	5,472.91	9,009.66
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(189.50)	599.54	(507.40)	410.04	(69.94)	(68.24)
	d. Employees benefits expense	4,033.19	4,097.01	3,553.23	8,130.20	7,271.50	14,681.81
	e. Depreciation and amortization expense	1,004.00	977.00	1,001.00	1,981.00	1,991.00	3,759.99
	f. Exchange Fluctuation Transactional (Gain)/Loss	86.78	118.72	25.97	205.50	(23.48)	58.16
	g. Other Expenses	7,556.39	7,320.63	7,422.79	14,877.02	14,000.81	28,633.60
	<b>Total Expenses</b>	<b>24,314.30</b>	<b>24,444.98</b>	<b>23,270.30</b>	<b>48,759.28</b>	<b>45,685.27</b>	<b>90,233.71</b>
3	<b>Profit from Operations before Other Income, Finance Cost (1-2)</b>	<b>4,363.80</b>	<b>3,975.87</b>	<b>4,755.47</b>	<b>8,339.67</b>	<b>8,600.78</b>	<b>15,908.41</b>
4	<b>Other Income</b>	<b>2,651.63</b>	<b>429.71</b>	<b>520.52</b>	<b>3,081.34</b>	<b>694.48</b>	<b>1,040.88</b>
5	<b>Profit before Finance Cost (3+4)</b>	<b>7,015.43</b>	<b>4,405.58</b>	<b>5,275.99</b>	<b>11,421.01</b>	<b>9,295.26</b>	<b>16,949.29</b>
6	<b>Finance Cost</b>	<b>308.41</b>	<b>171.03</b>	<b>225.40</b>	<b>479.44</b>	<b>357.97</b>	<b>665.01</b>
7	<b>Profit after Finance Cost but before Exchange Fluctuation Translation Gain / (Loss) (5-6)</b>	<b>6,707.02</b>	<b>4,234.55</b>	<b>5,050.59</b>	<b>10,941.57</b>	<b>8,937.29</b>	<b>16,284.28</b>
8	<b>Exchange Fluctuation Translation Gain / (Loss)</b>	<b>(478.49)</b>	<b>398.64</b>	<b>(782.29)</b>	<b>(79.85)</b>	<b>(413.52)</b>	<b>(373.86)</b>
9	<b>Profit before Tax (7+-8)</b>	<b>6,228.53</b>	<b>4,633.19</b>	<b>4,268.30</b>	<b>10,861.72</b>	<b>8,523.77</b>	<b>15,910.42</b>
10	<b>Tax expenses</b>	<b>1,330.00</b>	<b>1,205.00</b>	<b>1,079.57</b>	<b>2,535.00</b>	<b>2,155.94</b>	<b>4,552.17</b>
11	<b>Net Profit/(Loss) after Tax (9-10)</b>	<b>4,898.53</b>	<b>3,428.19</b>	<b>3,188.72</b>	<b>8,326.72</b>	<b>6,367.83</b>	<b>11,358.25</b>
12	<b>Paid Up Equity Share Capital (Face Value Rs.2/-)</b>	<b>1,696.40</b>	<b>1,696.16</b>	<b>1,696.16</b>	<b>1,696.40</b>	<b>1,696.16</b>	<b>1,696.16</b>
13	<b>Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year</b>	-	-	-	-	-	<b>99,934.99</b>
14	<b>(i) Earning per share(EPS) (of Rs. 2/- each not annualised)</b>						
	(1) Basic	5.78	4.04	3.76	9.82	7.51	13.40
	(2) Diluted	5.78	4.04	3.76	9.82	7.51	13.39

Sl. No.	PART II - Particulars	Quarter ended			Half Year		Year ended
		30/09/2015	30/06/2015	30/09/2014	30/09/2015	30/09/2014	31/03/2015
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
A	<b>PARTICULARS OF SHAREHOLDING</b>						
1	<b>Public Shareholding</b>						
	- Number of Shares	3,75,14,638	3,75,02,888	3,75,01,697	3,75,14,638	3,75,01,697	3,75,02,888
	- Percentage of shareholding	44.23	44.22	44.22	44.23	44.22	44.22
2	<b>Promoters and Promoter Group Shareholding</b>						
	a) Pledged/Encumbered						
	- Number of Shares	-	-	-	-	-	-
	- Percentage of shares (as a % of the shareholding of promoter and promoter group)	-	-	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the company)	-	-	-	-	-	-
	b) Non-encumbered						
	- Number of Shares	4,73,05,337	4,73,05,337	4,73,06,528	4,73,05,337	4,73,06,528	4,73,05,337
	- Percentage of shares (as a % of the shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of shares (as a % of the total share capital of the company)	55.77	55.78	55.78	55.77	55.78	55.78

# Unique



## J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:  
"NEELAM CENTRE", 'B' WING, 4TH FLR..  
HIND CYCLE ROAD, WORLI,  
MUMBAI - 400 030.

PHONE : 022-2482 2222 / 2493 0918  
FAX : 022-2493 0534 / 2493 9633  
e-mail : info@jbcpl.com  
Website : www.jbcpl.com  
CIN : L24390MH1976PLC019380

### B INVESTOR COMPLAINTS

Particulars	3 Months ended 30/09/2015
Pending at the beginning of the quarter	0
Received during the quarter	9
Disposed of during the quarter	9
Remaining unresolved at the end of the quarter	0

### NOTES

- The above financial results have been reviewed by the audit committee and approved by the board of directors at its meeting held on November 4, 2015.
- The statutory auditors have carried out limited review of the above financial results for the quarter ended on September 30, 2015.
- The increase in other income represents gain on sale/ redemption of investments.
- The company is engaged in a single segment of activity viz. Pharmaceuticals.
- The statement of assets and liabilities as of September 30, 2015 is as under:

		(Rs. in lakhs)	
Particulars		AS AT 30/09/2015	AS AT 31/03/2015
<b>A</b>	<b>EQUITY AND LIABILITIES</b>		
1	Shareholders' funds		
	a. Share Capital	1,696.40	1,696.16
	b. Reserves and surplus	1,08,270.82	99,934.99
	Sub Total of Shareholders' funds	1,09,967.22	1,01,631.15
2	Non-current liabilities		
	a. Long-term borrowings	-	40.00
	b. Deferred tax liabilities (Net)	2,247.22	2,162.22
	c. Long-term provisions	1,341.58	1,202.60
	Sub-Total - Non-current liabilities	3,588.80	3,404.82
3	Current liabilities		
	a. Short-term borrowings	14,172.95	10,472.97
	b. Trade payables	6,037.85	6,230.76
	c. Other current liabilities	10,016.62	8,259.92
	d. Short-term provisions	647.19	14,876.41
	Sub-Total - Current liabilities	30,874.61	39,840.06
	<b>TOTAL-EQUITY AND LIABILITIES</b>	<b>1,44,430.63</b>	<b>1,44,876.03</b>
<b>B</b>	<b>ASSETS</b>		
1	Non-current assets		
	a. Fixed assets	44,966.19	35,604.09
	b. Non-current investments	23,071.57	23,071.57
	c. Long-term loans and advances	1,637.02	1,201.91
	Sub-Total - Non-current assets	69,674.78	59,877.57
2	Current assets		
	a. Current investments	23,925.22	36,678.17
	b. Inventories	12,328.41	12,847.40
	c. Trade receivables	28,522.12	24,849.05
	d. Cash and cash equivalents	629.60	905.52
	e. Short-term loans and advances	9,350.50	9,718.32
	f. Other current assets	-	-
	Sub-Total - Current assets	74,755.85	84,998.46
	<b>TOTAL-ASSETS</b>	<b>1,44,430.63</b>	<b>1,44,876.03</b>

The previous quarter's/period's figures have been regrouped/re-stated, wherever necessary.

For J.B. Chemicals & Pharmaceuticals Ltd.

  
J.B. Mody  
Chairman & Managing Director

Place : Mumbai  
Date : November 4, 2015



REPORT OF THE LIMITED REVIEW

To  
The Board of Directors of  
**J. B. CHEMICALS & PHARMACEUTICALS LTD.**

We have reviewed the accompanying statement of unaudited financial results of **J. B. CHEMICALS & PHARMACEUTICALS LTD.** for the period ended 30<sup>th</sup> September, 2015 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.


We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Engagement to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards as per section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rule, 2014 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **J. K. Shah & Co.**  
Chartered Accountants  
Firm Regn. No. 109606W



**J.K. Shah**  
Partner  
Membership No. 03662



Place: Mumbai  
Date: 4<sup>th</sup> November, 2015

# Unique



## J. B. CHEMICALS & PHARMACEUTICALS LIMITED


REGD. OFFICE:  
"NEELAM CENTRE", 'B' WING, 4TH FLR.,  
HIND CYCLE ROAD, WORLI,  
MUMBAI - 400 030.

PHONE : 022-2482 2222 / 2493 0918  
FAX : 022-2493 0534 / 2493 9633  
e-mail : info@jbcpl.com  
Website : www.jbcpl.com  
CIN : L24390MH1976PLC019380

### STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30/09/2015

Sl.No.	PART I - Particulars	Quarter ended			Half Year		Year ended
		30/09/2015	30/06/2015	30/09/2014	30/09/2015	30/09/2014	31/03/2015
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	<b>Income from Operations</b>						
	a. Net sales (Net of excise duty)	28,070.95	27,914.93	27,486.10	55,985.88	53,157.31	1,03,813.61
	b. Other Operating Income	607.15	505.92	539.67	1,113.07	1,128.74	2,328.51
	<b>Total Income from Operations (Net) (a+b)</b>	<b>28,678.10</b>	<b>28,420.85</b>	<b>28,025.77</b>	<b>57,098.95</b>	<b>54,286.05</b>	<b>1,06,142.12</b>
2	<b>Expenses</b>						
	a. Cost of materials consumed	9,819.75	9,022.98	8,703.83	18,842.73	17,042.47	34,158.73
	b. Purchases of stock-in-trade	2,003.69	2,309.10	3,070.88	4,312.79	5,472.91	9,009.66
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(189.50)	599.54	(507.40)	410.04	(69.94)	(68.24)
	d. Employees benefits expense	4,033.19	4,097.01	3,553.23	8,130.20	7,271.50	14,681.81
	e. Depreciation and amortization expense	1,004.00	977.00	1,001.00	1,981.00	1,991.00	3,759.99
	f. Exchange Fluctuation Transactional (Gain)/Loss	86.78	118.72	25.97	205.50	(23.48)	58.16
	g. Other Expenses	7,556.39	7,320.63	7,422.79	14,877.02	14,000.81	28,633.60
	<b>Total Expenses</b>	<b>24,314.30</b>	<b>24,444.98</b>	<b>23,270.30</b>	<b>48,759.28</b>	<b>45,685.27</b>	<b>90,233.71</b>
3	Profit from Operations before Other Income, Finance Cost (1-2)	4,363.80	3,975.87	4,755.47	8,339.67	8,600.78	15,908.41
4	Other Income	2,651.63	429.71	520.52	3,081.34	694.48	1,040.88
5	Profit before Finance Cost (3+4)	7,015.43	4,405.58	5,275.99	11,421.01	9,295.26	16,949.29
6	Finance Cost	308.41	171.03	225.40	479.44	357.97	665.01
7	Profit after Finance Cost but before Exchange Fluctuation Translation Gain / (Loss) (5-6)	6,707.02	4,234.55	5,050.59	10,941.57	8,937.29	16,284.28
8	Exchange Fluctuation Translation Gain / (Loss)	(478.49)	398.64	(782.29)	(79.85)	(413.52)	(373.86)
9	Profit before Tax (7+-8)	6,228.53	4,633.19	4,268.30	10,861.72	8,523.77	15,910.42
10	Tax expenses	1,330.00	1,205.00	1,079.57	2,535.00	2,155.94	4,552.17
11	<b>Net Profit/(Loss) after Tax (9-10)</b>	<b>4,898.53</b>	<b>3,428.19</b>	<b>3,188.72</b>	<b>8,326.72</b>	<b>6,367.83</b>	<b>11,358.25</b>
12	Paid Up Equity Share Capital (Face Value Rs. 2/-)	1,696.40	1,696.16	1,696.16	1,696.40	1,696.16	1,696.16
13	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	-	-	-	-	-	99,934.99
14	(i) Earning per share(EPS) (of Rs. 2/- each not annualised)						
	(1) Basic	5.78	4.04	3.76	9.82	7.51	13.40
	(2) Diluted	5.78	4.04	3.76	9.82	7.51	13.39

Sl. No.	PART II - Particulars	Quarter ended			Half Year		Year ended
		30/09/2015	30/06/2015	30/09/2014	30/09/2015	30/09/2014	31/03/2015
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
A	<b>PARTICULARS OF SHAREHOLDING</b>						
1	Public Shareholding						
	- Number of Shares	3,75,14,638	3,75,02,888	3,75,01,697	3,75,14,638	3,75,01,697	3,75,02,888
	- Percentage of shareholding	44.23	44.22	44.22	44.23	44.22	44.22
2	Promoters and Promoter Group Shareholding						
	a) Pledged/Encumbered						
	- Number of Shares	-	-	-	-	-	-
	- Percentage of shares (as a % of the shareholding of promoter and promoter group)	-	-	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the company)	-	-	-	-	-	-
	b) Non-encumbered						
	- Number of Shares	4,73,05,337	4,73,05,337	4,73,06,528	4,73,05,337	4,73,06,528	4,73,05,337
	- Percentage of shares (as a % of the shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of shares (as a % of the total share capital of the company)	55.77	55.78	55.78	55.77	55.78	55.78



# Unique



## J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:  
"NEELAM CENTRE", 'B WING, 4TH FLR.,  
HIND CYCLE ROAD, WORLI,  
MUMBAI - 400 030.

PHONE : 022-2482 2222 / 2493 0918  
FAX : 022-2493 0534 / 2493 9633  
e-mail : info@jbcpl.com  
Website : www.jbcpl.com  
CIN : L24390MH1976PLC019380

### B INVESTOR COMPLAINTS

Particulars	3 Months ended 30/09/2015
Pending at the beginning of the quarter	0
Received during the quarter	9
Disposed of during the quarter	9
Remaining unresolved at the end of the quarter	0


### NOTES

1. The above financial results have been reviewed by the audit committee and approved by the board of directors at its meeting held on November 4, 2015.
2. The statutory auditors have carried out limited review of the above financial results for the quarter ended on September 30, 2015.
3. The increase in other income represents gain on sale/ redemption of investments.
4. The company is engaged in a single segment of activity viz. Pharmaceuticals.
5. The statement of assets and liabilities as of September 30, 2015 is as under:


		(Rs. in lakhs)	
	Particulars	AS AT 30/09/2015	AS AT 31/03/2015
<b>A</b>	<b>EQUITY AND LIABILITIES</b>		
1	Shareholders' funds		
	a. Share Capital	1,696.40	1,696.16
	b. Reserves and surplus	1,08,270.82	99,934.99
	Sub Total of Shareholders' funds	1,09,967.22	1,01,631.15
2	Non-current liabilities		
	a. Long-term borrowings	-	40.00
	b. Deferred tax liabilities (Net)	2,247.22	2,162.22
	c. Long-term provisions	1,341.58	1,202.60
	Sub-Total - Non-current liabilities	3,588.80	3,404.82
3	Current liabilities		
	a. Short-term borrowings	14,172.95	10,472.97
	b. Trade payables	6,037.85	6,230.76
	c. Other current liabilities	10,016.62	8,259.92
	d. Short-term provisions	647.19	14,876.41
	Sub-Total - Current liabilities	30,874.61	39,840.06
	<b>TOTAL-EQUITY AND LIABILITIES</b>	<b>1,44,430.63</b>	<b>1,44,876.03</b>
<b>B</b>	<b>ASSETS</b>		
1	Non-current assets		
	a. Fixed assets	44,966.19	35,604.09
	b. Non-current investments	23,071.57	23,071.57
	c. Long-term loans and advances	1,637.02	1,201.91
	Sub-Total - Non-current assets	69,674.78	59,877.57
2	Current assets		
	a. Current investments	23,925.22	36,678.17
	b. Inventories	12,328.41	12,847.40
	c. Trade receivables	28,522.12	24,849.05
	d. Cash and cash equivalents	629.60	905.52
	e. Short-term loans and advances	9,350.50	9,718.32
	f. Other current assets	-	-
	Sub-Total - Current assets	74,755.85	84,998.46
	<b>TOTAL-ASSETS</b>	<b>1,44,430.63</b>	<b>1,44,876.03</b>

The previous quarter's/period's figures are not audited/re-audited/re-stated, wherever necessary.

Place : Mumbai  
Date : November 4, 2015



For J.B. Chemicals & Pharmaceuticals Ltd.

  
J.B. Mody  
Chairman & Managing Director